Indexed In : Science Citation Index Expanded(SCIE), MEDLINE,
Pubmed/Pubmed Central, Elsevier Bibliographic, Google Scholar,
Databases(Scopus & Embase), KCI, KoreaMed, DOAJ
Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE
Yong Chan Lee |
Professor of Medicine Director, Gastrointestinal Research Laboratory Veterans Affairs Medical Center, Univ. California San Francisco San Francisco, USA |
Jong Pil Im | Seoul National University College of Medicine, Seoul, Korea |
Robert S. Bresalier | University of Texas M. D. Anderson Cancer Center, Houston, USA |
Steven H. Itzkowitz | Mount Sinai Medical Center, NY, USA |
All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.
The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.
Chin-Hee Song1, Nayoung Kim1,2, Sung Hwa Sohn1, Sun Min Lee1, Ryoung Hee Nam1, Hee Young Na4, Dong Ho Lee1,2, Young-Joon Surh3
Correspondence to: Correspondence to: Nayoung Kim
Department of Internal Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea
Tel: +82-31-787-7008, Fax: +82-31-787-4051, E-mail: nayoungkim49@empas.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gut Liver 2018;12(6):682-693. https://doi.org/10.5009/gnl18221
Published online October 29, 2018, Published date November 15, 2018
Copyright © Gut and Liver.
Intestinal barrier dysfunction is a hallmark of inflammatory bowel diseases (IBDs) such as ulcerative colitis. This dysfunction is caused by increased permeability and the loss of tight junctions in intestinal epithelial cells. The aim of this study was to investigate whether estradiol treatment reduces colonic permeability, tight junction disruption, and inflammation in an azoxymethane (AOM)/dextran sodium sulfate (DSS) colon cancer mouse model. The effects of 17β-estradiol (E2) were evaluated in ICR male mice 4 weeks after AOM/DSS treatment. Histological damage was scored by hematoxylin and eosin staining and the levels of the colonic mucosal cytokine myeloperoxidase (MPO) were assessed by enzyme-linked immunosorbent assay (ELISA). To evaluate the effects of E2 on intestinal permeability, tight junctions, and inflammation, we performed quantitative real-time polymerase chain reaction and Western blot analysis. Furthermore, the expression levels of mucin 2 (MUC2) and mucin 4 (MUC4) were measured as target genes for intestinal permeability, whereas zonula occludens 1 (ZO-1), occludin (OCLN), and claudin 4 (CLDN4) served as target genes for the tight junctions. The colitis-mediated induced damage score and MPO activity were reduced by E2 treatment (p<0.05). In addition, the mRNA expression levels of intestinal barrier-related molecules (i.e., MUC2, ZO-1, OCLN, and CLDN4) were decreased by AOM/DSS-treatment; furthermore, this inhibition was rescued by E2 supplementation. The mRNA and protein expression of inflammation-related genes (i.e., KLF4, NF-κB, iNOS, and COX-2) was increased by AOM/DSS-treatment and ameliorated by E2. E2 acts through the estrogen receptor β signaling pathway to elicit anti-inflammatory effects on intestinal barrier by inducing the expression of MUC2 and tight junction molecules and inhibiting pro-inflammatory cytokines.Background/Aims
Methods
Results
Conclusions
Keywords: AOM/DSS colitis mouse model, Permeability, Tight junction, Inflammation, Estrogen
Colorectal cancer (CRC) is the third leading cause of cancer deaths in both men and women in the United States, with an estimated 97,220 new cancer cases and 50,630 cancer deaths in 20181 and the major cause of death in women with age above 65 years old in Korea.2 When CRC occurs in the patients with inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn’s disease, which are a chronic disorder of the intestine,3 their progression to CRC is strongly associated with extent of inflammation and duration of IBD. Chronic inflammatory status drive cells to malignant transformation to promote tumorigenesis by oxidative stress and the pro-inflammatory factors such as interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α) and myeloperoxidase (MPO).4,5
The most widely used animal models in the investigation of the molecular pathogenesis in colitis and colitis-associated CRC is a mouse model with azoxymethane (AOM) and dextran sulfate sodium (DSS)6–8 mainly because it is a powerful, reproducible, and cost-effective model that utilize toxic chemical induction of oxidative DNA damage.9–11 Furthermore, this model is simulates the multistep tumor progression based on the aberrant crypt foci-adenoma-carcinoma sequence with the molecular alterations assessed in specific phases of the carcinogenic process.10
Intestinal barrier dysfunction is a hallmark IBD and it is caused by increased permeability and loss of tight junctions (TJs) in intestinal epithelial cells. The intestinal barrier is mainly composed of the mucus and the epithelial TJs which are proposed as potential markers of intestinal permeability.12–16 It is regulated by multiple factors such as the intestinal microbiota,17 food,18 cytokines and immune cells.19 At this point, the intestinal epithelium plays a key role to prevent permeation regulated by intestinal permeability modulating factors. In addition, the most important barrier is composed of colonic mucin, which is secreted from the colonic mucosa. The major component of the colonic mucus layer is the gel-forming mucin 2 (MUC2) and MUC2 knockout mice spontaneously developed colitis and CRC.20,21 In contrast, MUC4 knockout mice were found to be highly resistant to chemical-induced colitis and CRC.22 Another epithelial TJ molecules act as key multi-protein complexes to maintain the intestinal barrier while regulating permeability of nutrients and water.23 There are many evidences that the expressions of mucin and TJ molecules become different in the CRC in comparison to normal conditions. That is, the expression of Zonula occludens-1 (ZO-1) and occludin (OCLN) was down-regulated in CRC, but the expressions of claudin (CLDN) 1, 2, 3, and 4 were up-regulated in CRC.24 In addition, an over expression of protease-activated receptor 2 (PAR-2), which is a family member of G protein-coupled receptors, associated with the increased mucosal permeability in a guinea pig model of postoperative ileus25 and reflux esophagitis in human.26
Epidemiological, clinical and experimental studies reported that 17β-estradiol (E2), the predominant form of estrogen, confers protection against colon cell proliferation and malignant transformation, reducing the incidence of adenoma and carcinoma in colon.27,28 The physiological effects of estrogens are mediated by its receptors which are estrogen receptor α (ERα) and β (ERβ) encoded by different genes, and they have different expression patterns in colon. ERα was minimally expressed in colon cancer cells, and ERβ expression was significantly lower in colon cancer cells than in normal colonic epithelium.27 In addition, ERβ-selective agonists have been proposed to be therapeutically effective in the model of IBD and arthritis.29
Our research team have previously reported that colitis-associated colon carcinogenesis in AOM/DSS murine model was induced more severely in male mice than female by way of the inflammatory mediators such as IL-1β and MPO.30 Furthermore, we found that E2 (10 mg/kg), the major female sex hormone, inhibited the initiation of CRC by up-regulating nuclear factor erythroid 2-related factor 2, a transcriptional factor-related pathways in the AOM/DSS-treated male ICR mice.28
From this background, we hypothesized that estrogen inhibits AOM/DSS-colitis induced intestinal permeability and inflammation. To evaluate this hypothesis, the aim of this study was to investigate the levels of colonic mucosal cytokine and the gene expressions related to permeability, TJs, and inflammation in male AOM/DSS with or without E2, and to compare these markers between male and female mice.
Four-week-old male and female ICR mice (Orient Co., Ltd., Seoul, Korea) were housed in cages and maintained at 23°C with a 12/12-hour light/dark cycle under specific pathogen-free conditions. All animal experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Seoul National University Bundang Hospital (BA1310-139/091-01). The procedures were in accordance with the ARRIVE (Animals in Research: Reporting In Vivo Experiments) statement.
The experimental design is presented in Fig. 1A. After 1 week of acclimatization, male and female mice were randomized into five groups. Group 1 comprised male control mice (M_Con.) (n=4). Group 2 comprised male mice treated with AOM/DSS (M_ AOM/DSS) (n=6). Group 3 comprised AOM/DSS-treated male mice administered estradiol (M_AOM/DSS/E2) (n=6). Group 4 comprised female control mice (F_Con.) (n=4). Group 5 comprised AOM/DSS-treated female mice (F_AOM/DSS) (n=6). AOM/DSS-treated male and female mice were intraperitoneally injected with AOM (10 mg/kg; Sigma-Aldrich, St. Louis, MO, USA) on day 0 in the experimental schedule. For induction of colitis, 2.5% (w/v) DSS (MP Biomedicals, Aurora, OH, USA) was supplied in drinking water for 7 days 1 week following the injection of AOM31. The quantity of DSS consumed in the drinking water was checked on day 7, 9, and 11. M_AOM/DSS/E2 mice were intraperitoneally injected each day for 7 days with E2 (10 mg/kg; Sigma-Aldrich, E8876) dissolved in olive oil. The injections were done during the same period of DSS consumption. Animals were euthanized by CO2 asphyxiation at week 4 after AOM injection (Fig. 1A).
The proximal colon up to 1.5 cm from the ileocecal valve, the rectum up to 1.5 cm from the anal verge, and the colonic segments containing any grossly proven polyps were fixed with phosphate-buffered formalin and embedded in paraffin. The 5-mm sections were stained with hematoxylin and eosin. Histological severity was assessed using microscopic damage score reflecting colonic epithelial damage and depth of infiltration with inflammatory cells as previously described.32 It was evaluated by two researchers in a blinded manner.
Immunohistochemical (IHC) analysis of ZO-1 was performed. Tissue sections were treated with 3% hydrogen peroxide and nonspecific binding sites were blocked. The sections were incubated with anti-ZO-1 antibodies (61-7300, Thermo Fisher Scientific, Waltham, MA, USA). An automatic immunostainer (BenchMark XT; Ventana Medical Systems, Inc, Tucson, AZ, USA) and UltraView Universal DAB detection kit (Ventana Medical Systems) were used for immunostaining. The expression percentage was assessed as the ratio of the number of the cells stained with ZO-1 to the total cells counted per section. ZO-1 expression was quantified using ImageJ 1.50i software, with the Cell Counter plugin. The reported values are the average of different images from different mice within each group.
The levels of MPO activity in the colonic tissues were measured using a mouse MPO enzyme-linked immunosorbent assay kit (Hycult Biotechnology, The Netherlands), according to the manufacturer’s instruction. Every assay was performed in triplicate.
Total RNA was prepared from colon tissue using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instruments, and quantified using a NanoDrop ND-1000 device (Thermo Scientific, Wilmington, DE, USA). Complementary DNA (cDNA) was synthesized using the High Capacity cDNA reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). The cDNA was used to perform quantitative real-time polymerase chain reaction (qRT-PCR) using specific primers (listed in Table 1) and Power SYBR Green PCR Master mix (Thermo Fisher Scientific) in Viia7 instrument (Applied Biosystems). Expression levels of the genes were normalized to that of GAPDH.
Total protein was extracted from colon tissue using RIPA buffer (Cell Signaling Technology, Beverly, MA, USA) containing protease and phosphatase inhibitors. Cytoplasmic and nuclear lysates were separated using a NE-PER Nuclear Cytoplasmic Extraction Reagent kit (Pierce, Rockford, IL, USA) according to the manufacturer’s instructions. Protein concentration was determined using the BCA protein assay reagent (Pierce). Protein samples were mixed with an equal volume of 5× sodium do-decyl sulfate (SDS) sample buffer, boiled for 5 minutes, and then separated using 8% to 15% SDS-PAGE. After electrophoresis, proteins were transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% nonfat dry milk in tris-buffered saline with 0.1% Tween-20 buffer (TBS-T) for 1 hour at room temperature. Membranes were incubated overnight at 4°C with specific antibodies. Primary antibodies were removed by washing the membranes three times in TBS-T, and incubated for 2 hours with horseradish peroxidase-conjugated anti-rabbit, anti-goat or anti-mouse immunoglobulin (Santa Cruz Biotechnology, Dallas, TX, USA). Following three washes with TBS-T, the antigen-antibody complexes were detected with the ECL Prime Western Blotting Detection Kit (GE Healthcare Biosciences, Piscataway, NJ, USA). The intensity of the blots was quantified by densitometry analysis using ImageJ software (National Institutes of Health, Bethesda, MD, USA). The antibodies are listed in detail in the Table 2.
Data are expressed as mean±standard error of the mean. Statistical significance was examined with Mann-Whitney test or Fisher exact test. A p-value<0.05 was considered to indicate a statistical significance. All statistical analyses were conducted using GraphPad Prism software (GraphPad, La Jolla, CA, USA) and SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).
We first analyzed severity of colitis to evaluate early impacts of estradiol. Representative histologic photos (Fig. 1B) and microscopic damage score (Fig. 1C) showed that the AOM/DSS-treated male mice with E2 administration had significantly less infiltration of inflammatory cells and mild cryptic damage compared to the AOM/DSS-treated male mice on week 4 (p=0.054 for microscopic damage score) (Fig. 1C). The AOM/DSS-treated male mice with E2 administration showed significantly lower level of MPO, a mediator associated with intestinal inflammation, compared to the AOM/DSS-treated male mice (p=0.015 for MPO activity) (Fig. 1D). Taken together, our findings suggest that estrogen reduces the severity of colitis.
Since MUC2 is the major secreted mucin within the goblet cells in both the small and large intestine and it acts as the fundamental component of the mucus barrier.33 MUC4 is one of the transmembrane mucins have a single membrane spanning region. To investigate the effect of E2 on the mucus layer as a first barrier on the intestinal protection, we analyzed the mRNA expression level of mucin genes (i.e., MUC2 and MUC4) in mouse colon tissue sample. As shown in Fig. 2A, the inhibited expression of MUC2 in AOM/DSS-treated male mice was recovered by E2 supplementation (p<0.001). In female, MUC2 mRNA expression was significantly diminished by AOM/DSS treatment compare to control (p=0.001) (Fig. 2A). In contrast to MUC2 gene expression regulation, in both male and female, MUC4 mRNA expression was enhanced by AOM/DSS treatment. In addition, the AOM/DSS-mediated enhanced expression of MUC4 was inhibited by E2 administration in male mice (p<0.001) (Fig. 2B). There was no difference between male and female in both genes. These results suggest that E2 promotes intestinal barrier function through regulation of mucin gene expression act as a first intestinal barrier.
Next, to figure out the additional effect of E2 on intestinal permeability, we assessed TJ molecules mRNA expression by qRT-PCR analysis. Among TJ molecules, ZO-1 mRNA expression was approximately 1.7-fold decreased by AOM/DSS treatment compare to control in male. And, the decreased expression was altered to basal level by E2 administration in AOM/DSS-treated male mice (p=0.001) (Fig. 3A). In addition, the mRNA expressions of OCLN and CLDN4 were approximately 2.6-fold (p<0.001) (Fig. 3B) and 4-fold (p=0.005) (Fig. 3C) diminished by AOM/DSS treatment, respectively. The down-regulated expressions were significantly recovered to basal level by E2 supplementation in AOM/DSS-treated male mice (p=0.018 for OCLN, p=0.004 for CLDN4). In contrast to male, the mRNA expressions of TJ molecules such as ZO-1, OCLN, and CLDN4 were strongly up-regulated by AOM/DSS treatment compare to control in female group (Fig. 3A–C). Consistent with mRNA expression, the percentage of ZO-1-positive cells stained into the plasma membrane was significantly repressed by AOM/DSS treatment compare to control in male (p<0.001) (Fig. 3D). And, the decreased expression was recovered by E2 supply in AOM/DSS-treated male mice (p=0.026) (Fig. 3D). In contrast to male, ZO-1-positive cells were approximately 2.5% increased by AOM/DSS treatment compare to control in female group, but not significantly (Fig. 3D). These data suggest that exogenous estrogen has protective role on the colitis-mediated intestinal permeability through up-regulation of TJ-related gene expression.
To further evaluate estrogen effects on inflammatory factors in molecular levels, we measured nuclear factor κB (NF-κB)-dependent pro-inflammatory cytokines, enzymes, and genes. At first, we determined the expression level of Krüppel-like factor 4 (KLF4) gene which is reported as an important mediator of DSS-induced colonic inflammation by modulating NF-κB signaling pathway.34 The AOM/DSS-treated male mice with E2 administration showed significantly reduced level of KLF4 mRNA expression in comparison to the AOM/DSS-treated male mice (p=0.018) (Fig. 4A). The AOM/DSS-treated female mice showed reduced level of KLF4 mRNA expression compare to the AOM/DSS-treated male mice without statistical significance (Fig. 4A). Consistent with KLF4 gene expression, NF-κB expression in the nucleus was decreased in the AOM/DSS-treated male mice with E2 administration compared to the AOM/DSS-treated male mice (Fig. 4B). The AOM/DSS-treated female mice also reduced NF-κB expression compared to the AOM/DSS-treated male mice (Fig. 4B).
Next, we assessed the levels of two major pro-inflammatory enzymes (i.e., inducible nitric oxide synthase [iNOS] and cyclo-oxygenase-2 [COX-2]) which are mainly regulated by NF-κB by Western blot analysis. The AOM/DSS-treated male mice with E2 administration showed significantly reduced levels of iNOS and COX-2 expression compared to the AOM/DSS-treated male mice (p=0.004 for iNOS and p=0.003 for COX-2) (Fig. 4C). The AOM/DSS-treated female mice showed reduced level of pro-inflammatory enzymes compare to the AOM/DSS-treated male mice without statistical significance (Fig. 4C). Subsequently, we measured mRNA expression of NF-κB-related pro-inflammatory cytokines (i.e., TNF-α, IL-6, and IL-1β) in the intestinal mucosa by qRT-PCR. The expression level of TNF-α, IL-6, and IL-1β in the AOM/DSS-treated male mice with E2 administration decreased compared to the AOM/DSS-treated male mice (p=0.002 for TNF-α, p=0.012 for IL-6, and p<0.001 for IL-1β) Fig. 4D–F). Moreover, the AOM/DSS-treated female mice enhanced pro-inflammatory cytokines compared to the AOM/DSS-treated male mice (p=0.024 for IL-1β) (Fig. 4D–F). The levels of pro-inflammatory enzyme and cytokine gene expression were consistent with the results of microscopic damage index in male group. Taken together, these observations suggested that E2 has anti-inflammatory effects, especially suppressing NF-κB-related inflammatory mediators.
Furthermore, we measured mRNA expression of ERs in the intestinal mucosa by qRT-PCR to verify the role of ERs on inflammation-mediated colonic mucosal permeability. As shown in Fig. 4D, ERα expression was significantly increased by AOM/DSS-treatment on both male and female group compared to control mice (p=0.093 for M_Con. vs M_AOM/DSS, p=0.026 for F_Con. vs F_AOM/DSS) (Fig. 4G). And the level was decreased by E2 administration compared to M_AOM/DSS group, but not significantly. On the contrary, ERβ expression was strongly repressed by AOM/DSS-treatment on both sex compared to control mice (p<0.001 for M_Con. vs M_AOM/DSS, p<0.001 for F_Con. vs F_AOM/DSS) (Fig. 4H). And the decreased level was significantly recovered by E2 supply compared to M_AOM/DSS (p<0.001) (Fig. 4H).
In the present study, we found that E2 has protective role on intestinal barrier in the transition stage from inflammation to cancer in colon. To investigate the estrogen effects on that, we used AOM/DSS-treated colitis mouse model, and collected and assessed samples of colon mucosa at week 4 after AOM injection in ICR mice. According to
Mucins are the main components of mucus that act the first protective barrier for epithelial surface. Mucins can be classified into two types, namely secreted mucins and membrane bound (transmembrane) mucins based on the structure and localization. Secreted mucins form a protective layer over organs that contact the external environment and creates a physical barrier against pathogens. Among secreted gel forming mucin, MUC2 is the major intestinal mucin, expressed by goblet cells of the small intestine37–39 and colorectum.34,37 MUC2 knockout mice exhibited colonic inflammation and spontaneous development of colitis and CRC,40 and MUC2 deficiency alters inflammatory and metabolic pathways in the mouse intestinal mucosa.41 In addition, Hsu
TJs are multi-protein complexes that form a barrier which is selectively permeable seal between adjacent epithelial cells and demarcates the boundary between apical and basolateral membrane domains.23 Major components of TJs are ZOs, OCLN, CLDNs, and junctional adhesion molecules (JAM). The modification of TJ molecules and paracellular permeability on the barrier function are regulated by various extracellular stimuli and are closely associated with maintaining homeostasis.46 In ulcerative colitis patients, over expressions of TJ molecules such as OCLN, CLDN-1, -4, and JAM-A, and down regulation of CLDN-2 expression were observed.47 According to Ueda
The NF-κB proteins are normally sequestered in the cytoplasm of unstimulated cells via interactions with a family of inhibitor proteins called IκBs.50 A well-known function of NF-κB which is a family of inducible transcription factors is regulation of a number of target genes involved in different processes of the immune and inflammatory responses.51 Recently, deregulated NF-κB activation has been implicated in the pathogenesis of a number of inflammatory diseases, such as rheumatoid arthritis, IBD, multiple sclerosis, atherosclerosis, systemic lupus erythematosus, type I diabetes, chronic obstructive pulmonary disease and asthma.52 Especially, strong evidence suggests the involvement of NF-κB in the pathogenesis of IBD53 and colitis-associated CRC.54 Constitutive NF-κB activation55,56 and genetic mutations in
Numerous evidence has been reported in the literature ascribing anti-inflammatory and anti-tumorigenic effects of estrogens in the colon.60,61 Furthermore, the risk of colon cancer in post-menopausal women was suppressed by hormone replacement therapy.62 Generally, intracellular signaling of estrogens is mediated by its association with their receptors, ERα and ERβ. In colonic epithelium, ERβ is the predominant functional ER subtype expressed63 and its levels are inhibited in CRC compared to normal colonic mucosa.27 These findings suggest that protective role of estrogens in the colon may be exerted via ERβ signaling. Furthermore, Saleiro
In conclusion, E2 administration suppressed the colitis-induced intestinal permeability and inflammation in experimentally induced colitis male mice. The protective effects of E2 appear to be associated with increment the mRNA expression level of MUC2 and TJ molecules, and blockade of pro-inflammatory mediators modulated by NF-κB-dependent signaling pathway. Especially, the gene expressions of TJ molecules were differently regulated by sex in AOM/DSS-induced colitis. These findings may provide a new mechanistic explanation by which E2 regulates the intestinal permeability and inflammation during the transition stage from colitis to CRC through regulation of ERs expression.
This work was supported by a grant from the National Research Foundation of Korea (NRF) funded by the government of the Republic of Korea (2016R1A2B4013133).
Author Contribution: Song CH drafted manuscript and performed molecular experiments; Kim N designed and supervised the experiments, and revised manuscript, Sohn SH, Lee SM, and Nam RH performed animal experiments; Na HY advised the IHC experiment of ZO-1; Lee DH and Surh YJ revised manuscript.
No potential conflict of interest relevant to this article was reported.
List of Oligonucleotides for qRT-PCR
Gene | Sequence (5′→3′) |
---|---|
MUC2 | F: TTT CAA GCA CCC CTG TAA CC |
R: AGG TCC TGG TGT TGA ACC TG | |
MUC4 | F: CCC CCA TCT TTC TGT CTC AA |
R: AGG ATG GAA TTG GTG TT TG | |
ZO-1 | F: ACT ATG ACC ATC GCC TAC GG |
R: GGG GAT GCT GAT TCT CAA AA | |
OCLN | F: CGG TAC AGC AGC AAT GGT AA |
R: CTC CCC ACC TGT CGT GTA GT | |
CLDN4 | F: GGG GAT CAT CCT GAG TTG TG |
R: CAC TGC ATC TGA CCT GTG CT | |
KLF4 | F: CCA AAG AGG GGA AGA AGG TC |
R: CTG TGT GAG TTC GCA GGT GT | |
TNF-α | F: ACG GCA TGG ATC TCA AAG AC |
R: GTG GGT GAG GAG CAC GTA GT | |
IL-6 | F: CTG CAA GAG ACT TCC ATC CAG TT |
R: GAA GTA GGG AAG GCC GTG G | |
IL-1β | F: CAG GCA GGC AGT ATC ACT CA |
R: TGT CCT CAT CCT GGA AGG TC | |
ERα | F: TGG GCT TAT TGA CCA ACC TAG CA |
R: AGA ATC TCC AGC CAG GCA CAC | |
ERβ | F: TCT TTG CTC CAG ACC TCG TT |
R: AAT CAT GGC CTT CAC ACA CA | |
GAPDH | F: TTC ACC ACC ATG GAG AAG GC |
R: GGC ATG GAC TGT GGT CAT GA |
qRT-PCR, quantitative real-time polymerase chain reaction; MUC2, mucin 2; MUC4, mucin 4; ZO-1, zonula occludens 1; OCLN, occludin; CLDN4, claudin 4; KLF4, Krüppel-like factor 4; TNF-α, tumor necrosis factor-α; IL, interleukin; ER, estrogen receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
List of Antibodies and Its Characteristics
Antigen | Antibody | Dilution |
---|---|---|
NF-κB P65 | Santa Cruz Biotechnology (sc8008) | WB (1:1,000) |
iNOS | BD Biosciences (#610328) | WB (1:500) |
COX-2 | Santa Cruz Biotechnology (sc1745) | WB (1:1,000) |
ZO-1 | Thermo Fisher Scientific (#61-7300) | IHC (1:100) |
β-Actin | Santa Cruz Biotechnology (sc47778) | WB (1:1,000) |
Lamin B | Santa Cruz Biotechnology (sc6216) | WB (1:1,000) |
NF-κB P65, nuclear factor κB P65; WB, Western blot; iNOS, inducible nitric oxide synthase; COX-2, cyclooxygenase-2; IHC, immunohistochemical; ZO-1, zonula occludens 1.
Gut and Liver 2018; 12(6): 682-693
Published online November 15, 2018 https://doi.org/10.5009/gnl18221
Copyright © Gut and Liver.
Chin-Hee Song1, Nayoung Kim1,2, Sung Hwa Sohn1, Sun Min Lee1, Ryoung Hee Nam1, Hee Young Na4, Dong Ho Lee1,2, Young-Joon Surh3
1Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, 2Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea, 3Tumor Microenvironment Global Core Research Center, Seoul National University College of Pharmacy, Seoul, Korea, 4Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea
Correspondence to:Correspondence to: Nayoung Kim
Department of Internal Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea
Tel: +82-31-787-7008, Fax: +82-31-787-4051, E-mail: nayoungkim49@empas.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Intestinal barrier dysfunction is a hallmark of inflammatory bowel diseases (IBDs) such as ulcerative colitis. This dysfunction is caused by increased permeability and the loss of tight junctions in intestinal epithelial cells. The aim of this study was to investigate whether estradiol treatment reduces colonic permeability, tight junction disruption, and inflammation in an azoxymethane (AOM)/dextran sodium sulfate (DSS) colon cancer mouse model. The effects of 17β-estradiol (E2) were evaluated in ICR male mice 4 weeks after AOM/DSS treatment. Histological damage was scored by hematoxylin and eosin staining and the levels of the colonic mucosal cytokine myeloperoxidase (MPO) were assessed by enzyme-linked immunosorbent assay (ELISA). To evaluate the effects of E2 on intestinal permeability, tight junctions, and inflammation, we performed quantitative real-time polymerase chain reaction and Western blot analysis. Furthermore, the expression levels of mucin 2 (MUC2) and mucin 4 (MUC4) were measured as target genes for intestinal permeability, whereas zonula occludens 1 (ZO-1), occludin (OCLN), and claudin 4 (CLDN4) served as target genes for the tight junctions. The colitis-mediated induced damage score and MPO activity were reduced by E2 treatment (p<0.05). In addition, the mRNA expression levels of intestinal barrier-related molecules (i.e., MUC2, ZO-1, OCLN, and CLDN4) were decreased by AOM/DSS-treatment; furthermore, this inhibition was rescued by E2 supplementation. The mRNA and protein expression of inflammation-related genes (i.e., KLF4, NF-κB, iNOS, and COX-2) was increased by AOM/DSS-treatment and ameliorated by E2. E2 acts through the estrogen receptor β signaling pathway to elicit anti-inflammatory effects on intestinal barrier by inducing the expression of MUC2 and tight junction molecules and inhibiting pro-inflammatory cytokines.Background/Aims
Methods
Results
Conclusions
Keywords: AOM/DSS colitis mouse model, Permeability, Tight junction, Inflammation, Estrogen
Colorectal cancer (CRC) is the third leading cause of cancer deaths in both men and women in the United States, with an estimated 97,220 new cancer cases and 50,630 cancer deaths in 20181 and the major cause of death in women with age above 65 years old in Korea.2 When CRC occurs in the patients with inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn’s disease, which are a chronic disorder of the intestine,3 their progression to CRC is strongly associated with extent of inflammation and duration of IBD. Chronic inflammatory status drive cells to malignant transformation to promote tumorigenesis by oxidative stress and the pro-inflammatory factors such as interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α) and myeloperoxidase (MPO).4,5
The most widely used animal models in the investigation of the molecular pathogenesis in colitis and colitis-associated CRC is a mouse model with azoxymethane (AOM) and dextran sulfate sodium (DSS)6–8 mainly because it is a powerful, reproducible, and cost-effective model that utilize toxic chemical induction of oxidative DNA damage.9–11 Furthermore, this model is simulates the multistep tumor progression based on the aberrant crypt foci-adenoma-carcinoma sequence with the molecular alterations assessed in specific phases of the carcinogenic process.10
Intestinal barrier dysfunction is a hallmark IBD and it is caused by increased permeability and loss of tight junctions (TJs) in intestinal epithelial cells. The intestinal barrier is mainly composed of the mucus and the epithelial TJs which are proposed as potential markers of intestinal permeability.12–16 It is regulated by multiple factors such as the intestinal microbiota,17 food,18 cytokines and immune cells.19 At this point, the intestinal epithelium plays a key role to prevent permeation regulated by intestinal permeability modulating factors. In addition, the most important barrier is composed of colonic mucin, which is secreted from the colonic mucosa. The major component of the colonic mucus layer is the gel-forming mucin 2 (MUC2) and MUC2 knockout mice spontaneously developed colitis and CRC.20,21 In contrast, MUC4 knockout mice were found to be highly resistant to chemical-induced colitis and CRC.22 Another epithelial TJ molecules act as key multi-protein complexes to maintain the intestinal barrier while regulating permeability of nutrients and water.23 There are many evidences that the expressions of mucin and TJ molecules become different in the CRC in comparison to normal conditions. That is, the expression of Zonula occludens-1 (ZO-1) and occludin (OCLN) was down-regulated in CRC, but the expressions of claudin (CLDN) 1, 2, 3, and 4 were up-regulated in CRC.24 In addition, an over expression of protease-activated receptor 2 (PAR-2), which is a family member of G protein-coupled receptors, associated with the increased mucosal permeability in a guinea pig model of postoperative ileus25 and reflux esophagitis in human.26
Epidemiological, clinical and experimental studies reported that 17β-estradiol (E2), the predominant form of estrogen, confers protection against colon cell proliferation and malignant transformation, reducing the incidence of adenoma and carcinoma in colon.27,28 The physiological effects of estrogens are mediated by its receptors which are estrogen receptor α (ERα) and β (ERβ) encoded by different genes, and they have different expression patterns in colon. ERα was minimally expressed in colon cancer cells, and ERβ expression was significantly lower in colon cancer cells than in normal colonic epithelium.27 In addition, ERβ-selective agonists have been proposed to be therapeutically effective in the model of IBD and arthritis.29
Our research team have previously reported that colitis-associated colon carcinogenesis in AOM/DSS murine model was induced more severely in male mice than female by way of the inflammatory mediators such as IL-1β and MPO.30 Furthermore, we found that E2 (10 mg/kg), the major female sex hormone, inhibited the initiation of CRC by up-regulating nuclear factor erythroid 2-related factor 2, a transcriptional factor-related pathways in the AOM/DSS-treated male ICR mice.28
From this background, we hypothesized that estrogen inhibits AOM/DSS-colitis induced intestinal permeability and inflammation. To evaluate this hypothesis, the aim of this study was to investigate the levels of colonic mucosal cytokine and the gene expressions related to permeability, TJs, and inflammation in male AOM/DSS with or without E2, and to compare these markers between male and female mice.
Four-week-old male and female ICR mice (Orient Co., Ltd., Seoul, Korea) were housed in cages and maintained at 23°C with a 12/12-hour light/dark cycle under specific pathogen-free conditions. All animal experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Seoul National University Bundang Hospital (BA1310-139/091-01). The procedures were in accordance with the ARRIVE (Animals in Research: Reporting In Vivo Experiments) statement.
The experimental design is presented in Fig. 1A. After 1 week of acclimatization, male and female mice were randomized into five groups. Group 1 comprised male control mice (M_Con.) (n=4). Group 2 comprised male mice treated with AOM/DSS (M_ AOM/DSS) (n=6). Group 3 comprised AOM/DSS-treated male mice administered estradiol (M_AOM/DSS/E2) (n=6). Group 4 comprised female control mice (F_Con.) (n=4). Group 5 comprised AOM/DSS-treated female mice (F_AOM/DSS) (n=6). AOM/DSS-treated male and female mice were intraperitoneally injected with AOM (10 mg/kg; Sigma-Aldrich, St. Louis, MO, USA) on day 0 in the experimental schedule. For induction of colitis, 2.5% (w/v) DSS (MP Biomedicals, Aurora, OH, USA) was supplied in drinking water for 7 days 1 week following the injection of AOM31. The quantity of DSS consumed in the drinking water was checked on day 7, 9, and 11. M_AOM/DSS/E2 mice were intraperitoneally injected each day for 7 days with E2 (10 mg/kg; Sigma-Aldrich, E8876) dissolved in olive oil. The injections were done during the same period of DSS consumption. Animals were euthanized by CO2 asphyxiation at week 4 after AOM injection (Fig. 1A).
The proximal colon up to 1.5 cm from the ileocecal valve, the rectum up to 1.5 cm from the anal verge, and the colonic segments containing any grossly proven polyps were fixed with phosphate-buffered formalin and embedded in paraffin. The 5-mm sections were stained with hematoxylin and eosin. Histological severity was assessed using microscopic damage score reflecting colonic epithelial damage and depth of infiltration with inflammatory cells as previously described.32 It was evaluated by two researchers in a blinded manner.
Immunohistochemical (IHC) analysis of ZO-1 was performed. Tissue sections were treated with 3% hydrogen peroxide and nonspecific binding sites were blocked. The sections were incubated with anti-ZO-1 antibodies (61-7300, Thermo Fisher Scientific, Waltham, MA, USA). An automatic immunostainer (BenchMark XT; Ventana Medical Systems, Inc, Tucson, AZ, USA) and UltraView Universal DAB detection kit (Ventana Medical Systems) were used for immunostaining. The expression percentage was assessed as the ratio of the number of the cells stained with ZO-1 to the total cells counted per section. ZO-1 expression was quantified using ImageJ 1.50i software, with the Cell Counter plugin. The reported values are the average of different images from different mice within each group.
The levels of MPO activity in the colonic tissues were measured using a mouse MPO enzyme-linked immunosorbent assay kit (Hycult Biotechnology, The Netherlands), according to the manufacturer’s instruction. Every assay was performed in triplicate.
Total RNA was prepared from colon tissue using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instruments, and quantified using a NanoDrop ND-1000 device (Thermo Scientific, Wilmington, DE, USA). Complementary DNA (cDNA) was synthesized using the High Capacity cDNA reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). The cDNA was used to perform quantitative real-time polymerase chain reaction (qRT-PCR) using specific primers (listed in Table 1) and Power SYBR Green PCR Master mix (Thermo Fisher Scientific) in Viia7 instrument (Applied Biosystems). Expression levels of the genes were normalized to that of GAPDH.
Total protein was extracted from colon tissue using RIPA buffer (Cell Signaling Technology, Beverly, MA, USA) containing protease and phosphatase inhibitors. Cytoplasmic and nuclear lysates were separated using a NE-PER Nuclear Cytoplasmic Extraction Reagent kit (Pierce, Rockford, IL, USA) according to the manufacturer’s instructions. Protein concentration was determined using the BCA protein assay reagent (Pierce). Protein samples were mixed with an equal volume of 5× sodium do-decyl sulfate (SDS) sample buffer, boiled for 5 minutes, and then separated using 8% to 15% SDS-PAGE. After electrophoresis, proteins were transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% nonfat dry milk in tris-buffered saline with 0.1% Tween-20 buffer (TBS-T) for 1 hour at room temperature. Membranes were incubated overnight at 4°C with specific antibodies. Primary antibodies were removed by washing the membranes three times in TBS-T, and incubated for 2 hours with horseradish peroxidase-conjugated anti-rabbit, anti-goat or anti-mouse immunoglobulin (Santa Cruz Biotechnology, Dallas, TX, USA). Following three washes with TBS-T, the antigen-antibody complexes were detected with the ECL Prime Western Blotting Detection Kit (GE Healthcare Biosciences, Piscataway, NJ, USA). The intensity of the blots was quantified by densitometry analysis using ImageJ software (National Institutes of Health, Bethesda, MD, USA). The antibodies are listed in detail in the Table 2.
Data are expressed as mean±standard error of the mean. Statistical significance was examined with Mann-Whitney test or Fisher exact test. A p-value<0.05 was considered to indicate a statistical significance. All statistical analyses were conducted using GraphPad Prism software (GraphPad, La Jolla, CA, USA) and SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).
We first analyzed severity of colitis to evaluate early impacts of estradiol. Representative histologic photos (Fig. 1B) and microscopic damage score (Fig. 1C) showed that the AOM/DSS-treated male mice with E2 administration had significantly less infiltration of inflammatory cells and mild cryptic damage compared to the AOM/DSS-treated male mice on week 4 (p=0.054 for microscopic damage score) (Fig. 1C). The AOM/DSS-treated male mice with E2 administration showed significantly lower level of MPO, a mediator associated with intestinal inflammation, compared to the AOM/DSS-treated male mice (p=0.015 for MPO activity) (Fig. 1D). Taken together, our findings suggest that estrogen reduces the severity of colitis.
Since MUC2 is the major secreted mucin within the goblet cells in both the small and large intestine and it acts as the fundamental component of the mucus barrier.33 MUC4 is one of the transmembrane mucins have a single membrane spanning region. To investigate the effect of E2 on the mucus layer as a first barrier on the intestinal protection, we analyzed the mRNA expression level of mucin genes (i.e., MUC2 and MUC4) in mouse colon tissue sample. As shown in Fig. 2A, the inhibited expression of MUC2 in AOM/DSS-treated male mice was recovered by E2 supplementation (p<0.001). In female, MUC2 mRNA expression was significantly diminished by AOM/DSS treatment compare to control (p=0.001) (Fig. 2A). In contrast to MUC2 gene expression regulation, in both male and female, MUC4 mRNA expression was enhanced by AOM/DSS treatment. In addition, the AOM/DSS-mediated enhanced expression of MUC4 was inhibited by E2 administration in male mice (p<0.001) (Fig. 2B). There was no difference between male and female in both genes. These results suggest that E2 promotes intestinal barrier function through regulation of mucin gene expression act as a first intestinal barrier.
Next, to figure out the additional effect of E2 on intestinal permeability, we assessed TJ molecules mRNA expression by qRT-PCR analysis. Among TJ molecules, ZO-1 mRNA expression was approximately 1.7-fold decreased by AOM/DSS treatment compare to control in male. And, the decreased expression was altered to basal level by E2 administration in AOM/DSS-treated male mice (p=0.001) (Fig. 3A). In addition, the mRNA expressions of OCLN and CLDN4 were approximately 2.6-fold (p<0.001) (Fig. 3B) and 4-fold (p=0.005) (Fig. 3C) diminished by AOM/DSS treatment, respectively. The down-regulated expressions were significantly recovered to basal level by E2 supplementation in AOM/DSS-treated male mice (p=0.018 for OCLN, p=0.004 for CLDN4). In contrast to male, the mRNA expressions of TJ molecules such as ZO-1, OCLN, and CLDN4 were strongly up-regulated by AOM/DSS treatment compare to control in female group (Fig. 3A–C). Consistent with mRNA expression, the percentage of ZO-1-positive cells stained into the plasma membrane was significantly repressed by AOM/DSS treatment compare to control in male (p<0.001) (Fig. 3D). And, the decreased expression was recovered by E2 supply in AOM/DSS-treated male mice (p=0.026) (Fig. 3D). In contrast to male, ZO-1-positive cells were approximately 2.5% increased by AOM/DSS treatment compare to control in female group, but not significantly (Fig. 3D). These data suggest that exogenous estrogen has protective role on the colitis-mediated intestinal permeability through up-regulation of TJ-related gene expression.
To further evaluate estrogen effects on inflammatory factors in molecular levels, we measured nuclear factor κB (NF-κB)-dependent pro-inflammatory cytokines, enzymes, and genes. At first, we determined the expression level of Krüppel-like factor 4 (KLF4) gene which is reported as an important mediator of DSS-induced colonic inflammation by modulating NF-κB signaling pathway.34 The AOM/DSS-treated male mice with E2 administration showed significantly reduced level of KLF4 mRNA expression in comparison to the AOM/DSS-treated male mice (p=0.018) (Fig. 4A). The AOM/DSS-treated female mice showed reduced level of KLF4 mRNA expression compare to the AOM/DSS-treated male mice without statistical significance (Fig. 4A). Consistent with KLF4 gene expression, NF-κB expression in the nucleus was decreased in the AOM/DSS-treated male mice with E2 administration compared to the AOM/DSS-treated male mice (Fig. 4B). The AOM/DSS-treated female mice also reduced NF-κB expression compared to the AOM/DSS-treated male mice (Fig. 4B).
Next, we assessed the levels of two major pro-inflammatory enzymes (i.e., inducible nitric oxide synthase [iNOS] and cyclo-oxygenase-2 [COX-2]) which are mainly regulated by NF-κB by Western blot analysis. The AOM/DSS-treated male mice with E2 administration showed significantly reduced levels of iNOS and COX-2 expression compared to the AOM/DSS-treated male mice (p=0.004 for iNOS and p=0.003 for COX-2) (Fig. 4C). The AOM/DSS-treated female mice showed reduced level of pro-inflammatory enzymes compare to the AOM/DSS-treated male mice without statistical significance (Fig. 4C). Subsequently, we measured mRNA expression of NF-κB-related pro-inflammatory cytokines (i.e., TNF-α, IL-6, and IL-1β) in the intestinal mucosa by qRT-PCR. The expression level of TNF-α, IL-6, and IL-1β in the AOM/DSS-treated male mice with E2 administration decreased compared to the AOM/DSS-treated male mice (p=0.002 for TNF-α, p=0.012 for IL-6, and p<0.001 for IL-1β) Fig. 4D–F). Moreover, the AOM/DSS-treated female mice enhanced pro-inflammatory cytokines compared to the AOM/DSS-treated male mice (p=0.024 for IL-1β) (Fig. 4D–F). The levels of pro-inflammatory enzyme and cytokine gene expression were consistent with the results of microscopic damage index in male group. Taken together, these observations suggested that E2 has anti-inflammatory effects, especially suppressing NF-κB-related inflammatory mediators.
Furthermore, we measured mRNA expression of ERs in the intestinal mucosa by qRT-PCR to verify the role of ERs on inflammation-mediated colonic mucosal permeability. As shown in Fig. 4D, ERα expression was significantly increased by AOM/DSS-treatment on both male and female group compared to control mice (p=0.093 for M_Con. vs M_AOM/DSS, p=0.026 for F_Con. vs F_AOM/DSS) (Fig. 4G). And the level was decreased by E2 administration compared to M_AOM/DSS group, but not significantly. On the contrary, ERβ expression was strongly repressed by AOM/DSS-treatment on both sex compared to control mice (p<0.001 for M_Con. vs M_AOM/DSS, p<0.001 for F_Con. vs F_AOM/DSS) (Fig. 4H). And the decreased level was significantly recovered by E2 supply compared to M_AOM/DSS (p<0.001) (Fig. 4H).
In the present study, we found that E2 has protective role on intestinal barrier in the transition stage from inflammation to cancer in colon. To investigate the estrogen effects on that, we used AOM/DSS-treated colitis mouse model, and collected and assessed samples of colon mucosa at week 4 after AOM injection in ICR mice. According to
Mucins are the main components of mucus that act the first protective barrier for epithelial surface. Mucins can be classified into two types, namely secreted mucins and membrane bound (transmembrane) mucins based on the structure and localization. Secreted mucins form a protective layer over organs that contact the external environment and creates a physical barrier against pathogens. Among secreted gel forming mucin, MUC2 is the major intestinal mucin, expressed by goblet cells of the small intestine37–39 and colorectum.34,37 MUC2 knockout mice exhibited colonic inflammation and spontaneous development of colitis and CRC,40 and MUC2 deficiency alters inflammatory and metabolic pathways in the mouse intestinal mucosa.41 In addition, Hsu
TJs are multi-protein complexes that form a barrier which is selectively permeable seal between adjacent epithelial cells and demarcates the boundary between apical and basolateral membrane domains.23 Major components of TJs are ZOs, OCLN, CLDNs, and junctional adhesion molecules (JAM). The modification of TJ molecules and paracellular permeability on the barrier function are regulated by various extracellular stimuli and are closely associated with maintaining homeostasis.46 In ulcerative colitis patients, over expressions of TJ molecules such as OCLN, CLDN-1, -4, and JAM-A, and down regulation of CLDN-2 expression were observed.47 According to Ueda
The NF-κB proteins are normally sequestered in the cytoplasm of unstimulated cells via interactions with a family of inhibitor proteins called IκBs.50 A well-known function of NF-κB which is a family of inducible transcription factors is regulation of a number of target genes involved in different processes of the immune and inflammatory responses.51 Recently, deregulated NF-κB activation has been implicated in the pathogenesis of a number of inflammatory diseases, such as rheumatoid arthritis, IBD, multiple sclerosis, atherosclerosis, systemic lupus erythematosus, type I diabetes, chronic obstructive pulmonary disease and asthma.52 Especially, strong evidence suggests the involvement of NF-κB in the pathogenesis of IBD53 and colitis-associated CRC.54 Constitutive NF-κB activation55,56 and genetic mutations in
Numerous evidence has been reported in the literature ascribing anti-inflammatory and anti-tumorigenic effects of estrogens in the colon.60,61 Furthermore, the risk of colon cancer in post-menopausal women was suppressed by hormone replacement therapy.62 Generally, intracellular signaling of estrogens is mediated by its association with their receptors, ERα and ERβ. In colonic epithelium, ERβ is the predominant functional ER subtype expressed63 and its levels are inhibited in CRC compared to normal colonic mucosa.27 These findings suggest that protective role of estrogens in the colon may be exerted via ERβ signaling. Furthermore, Saleiro
In conclusion, E2 administration suppressed the colitis-induced intestinal permeability and inflammation in experimentally induced colitis male mice. The protective effects of E2 appear to be associated with increment the mRNA expression level of MUC2 and TJ molecules, and blockade of pro-inflammatory mediators modulated by NF-κB-dependent signaling pathway. Especially, the gene expressions of TJ molecules were differently regulated by sex in AOM/DSS-induced colitis. These findings may provide a new mechanistic explanation by which E2 regulates the intestinal permeability and inflammation during the transition stage from colitis to CRC through regulation of ERs expression.
This work was supported by a grant from the National Research Foundation of Korea (NRF) funded by the government of the Republic of Korea (2016R1A2B4013133).
Author Contribution: Song CH drafted manuscript and performed molecular experiments; Kim N designed and supervised the experiments, and revised manuscript, Sohn SH, Lee SM, and Nam RH performed animal experiments; Na HY advised the IHC experiment of ZO-1; Lee DH and Surh YJ revised manuscript.
No potential conflict of interest relevant to this article was reported.
Table 1 List of Oligonucleotides for qRT-PCR
Gene | Sequence (5′→3′) |
---|---|
MUC2 | F: TTT CAA GCA CCC CTG TAA CC |
R: AGG TCC TGG TGT TGA ACC TG | |
MUC4 | F: CCC CCA TCT TTC TGT CTC AA |
R: AGG ATG GAA TTG GTG TT TG | |
ZO-1 | F: ACT ATG ACC ATC GCC TAC GG |
R: GGG GAT GCT GAT TCT CAA AA | |
OCLN | F: CGG TAC AGC AGC AAT GGT AA |
R: CTC CCC ACC TGT CGT GTA GT | |
CLDN4 | F: GGG GAT CAT CCT GAG TTG TG |
R: CAC TGC ATC TGA CCT GTG CT | |
KLF4 | F: CCA AAG AGG GGA AGA AGG TC |
R: CTG TGT GAG TTC GCA GGT GT | |
TNF-α | F: ACG GCA TGG ATC TCA AAG AC |
R: GTG GGT GAG GAG CAC GTA GT | |
IL-6 | F: CTG CAA GAG ACT TCC ATC CAG TT |
R: GAA GTA GGG AAG GCC GTG G | |
IL-1β | F: CAG GCA GGC AGT ATC ACT CA |
R: TGT CCT CAT CCT GGA AGG TC | |
ERα | F: TGG GCT TAT TGA CCA ACC TAG CA |
R: AGA ATC TCC AGC CAG GCA CAC | |
ERβ | F: TCT TTG CTC CAG ACC TCG TT |
R: AAT CAT GGC CTT CAC ACA CA | |
GAPDH | F: TTC ACC ACC ATG GAG AAG GC |
R: GGC ATG GAC TGT GGT CAT GA |
qRT-PCR, quantitative real-time polymerase chain reaction; MUC2, mucin 2; MUC4, mucin 4; ZO-1, zonula occludens 1; OCLN, occludin; CLDN4, claudin 4; KLF4, Krüppel-like factor 4; TNF-α, tumor necrosis factor-α; IL, interleukin; ER, estrogen receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Table 2 List of Antibodies and Its Characteristics
Antigen | Antibody | Dilution |
---|---|---|
NF-κB P65 | Santa Cruz Biotechnology (sc8008) | WB (1:1,000) |
iNOS | BD Biosciences (#610328) | WB (1:500) |
COX-2 | Santa Cruz Biotechnology (sc1745) | WB (1:1,000) |
ZO-1 | Thermo Fisher Scientific (#61-7300) | IHC (1:100) |
β-Actin | Santa Cruz Biotechnology (sc47778) | WB (1:1,000) |
Lamin B | Santa Cruz Biotechnology (sc6216) | WB (1:1,000) |
NF-κB P65, nuclear factor κB P65; WB, Western blot; iNOS, inducible nitric oxide synthase; COX-2, cyclooxygenase-2; IHC, immunohistochemical; ZO-1, zonula occludens 1.